Lymphopenia predicts poor outcomes in newly diagnosed multiple myeloma
Key PointsLymphopenia at diagnosis and follow-up predicts inferior OS in patients with MM.ALC is a readily available biomarker and predictor of outcomes in
Related Articles
Combination does not extend survival vs. chemotherapy in gastroesophageal cancer
The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced gastroesophageal adenocarcinoma, according to the agents’ manufacturers.However, the…
ESMO Guidelines: Real World Cases – Webinar Series: Renal Cell
This ESMO Webinar Series is available to all healthcare professionals working in Oncology
Fox Chase Cancer Center Welcomes Weiran Feng, PhD
Weiran Feng, PhD, Assistant Professor in the Nuclear Dynamics and Cancer Research Program and a member of the Cancer Epigenetics Institute (CEI).
How blood and bone marrow transplant expertise is changing cancer care at Ohio State
For four decades, Ohio State blood and bone marrow transplant innovation has improved cancer care with an increasing emphasis on patients’ quality of life.
Tackling Racial Gaps in Fatalism to Improve Indolent Blood Cancer Outcomes – Physician’s Weekly
Cancer-related fear and fatalism are more prevalent in patients of racial minority groups with indolent blood cancer, potentially impacting outcomes.
Rule Banning Menthol Cigarettes Nixed
The Trump Administration has withdrawn a proposed rule that would’ve banned menthol cigarettes and flavored cigars—even though all other flavorings have already been prohibited. The…
Valemetostat May Yield Durable Responses in PTCL – Oncology Nurse Advisor
Researchers sought to determine whether valemetostat would yield durable responses in patients with PTCL.
Program
Program for AACR Special Conference in Cancer Research: Functional and Genomic Precision Medicine in Cancer: Different Perspectives, Common Goals
Evorpacept Demonstrates Efficacy in HER2-Positive Gastric/GEJ Cancer
Phase 2 findings show clinical responses and improved survival with evorpacept in patients with HER2-positive gastric/gastroesophageal cancer.
Beyond the $500B Stargate Project: The frontier of AI in oncology beckons – The Cancer Letter
On Jan. 21, President Donald Trump announced the launch of the Stargate Project, a $500 billion artificial intelligence infrastructure project designed to revolutionize healthcare. To…
